I hope it is more than EIND data (that won’t be enough for a quantum step in the medical community, who want solid trial results) or trial enrollment updates. At this point investor calls should be more significant - which gets to the point that as the company gains more of a spotlight it really needs to focus and be judicious with that spotlight.